Log in to your Inderes Free account to see all free content on this page.
Chordate Medical Holding
15.65
SEK
+1.62 %
CMH
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
+1.62%
-34.79%
-33.4%
-39.58%
-74.31%
-83.48%
-95.49%
-92.72%
-99.19%
www.chordate.com/investor-relations
Chordate Medical Holding is a medical technology company that has developed, patented and CE-marked a nerve-modulating treatment technique for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (KOS). The company sells its products to treating clinics in selected European markets, Israel and Saudi Arabia, with the aim of increasing its presence in the global market.
Revenue
980K
EBIT %
-3,017.35 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CMH
Daily low / high price
15.45 / 15.65
SEK
Market cap
17.35M SEK
Turnover
7.82K SEK
Volume
500
Financial calendar
Annual report
28.02.2025
General meeting
21.05.2025
Interim report
23.05.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Lars Ingvarsson inkl bolag | 12.2 % | 12.2 % |
Hawoc Investment AB | 9.1 % | 9.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Last day of trading with warrants of series TO 8 in Chordate Medical Holding AB (publ)
Major Shareholders and Management Announce Intent to Exercise TO8 Warrants in Chordate Medical Holding AB (publ.)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio